Drug Approval | December 12, 2023
Merck Animal Health receives positive CVMP opinion for an injectable formulation of Bravecto
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Demonstrate significant bleed reduction in hemophilia A and B
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
New facility is part of Aptar Pharma’s global expansion program
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Express Scripts to add Zepbound to National Preferred Formulary
There has been no loss or injury to human life
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The company is assessing the situation and simultaneously undertaking all the requisite action
Subscribe To Our Newsletter & Stay Updated
